March 5, 2015 / 12:47 PM / 3 years ago

BUZZ-Oncolytics Biotech Inc: Presents cancer drug data at conference

** Canadian drug developer’s U.S.-listed shares up 5 pct at $1.06 premarket

** Company presents data at a conference on a combination of its lead cancer drug along with radiationtherapy in treating melanoma, a type of skin cancer

** Data shows reolysin, when combined with radiationtherapy, effective in destroying cancer cells

** Reolysin was granted orphan drug status by U.S. FDA to treat a type of abdomen and fallopian tube cancer

** Orphan drug status is granted to drugs being developed to treat rare diseases; it gives drug developer various incentives including a 7-year marketing exclusivity

** Up to Wednesday’s close, Oncolytics stock had gained 87 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below